Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Recruiting · NCT07166315 · Observational (researchers observe without assigning treatment) · Lead sponsor: Adelphi Real World
View the official record on ClinicalTrials.gov →Interventions studied
observational study
What this trial is about
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
- Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
- Participant is aged 18 years or older at enrolment.
Exclusion criteria
- Participation in a clinical trial at enrolment.
Where it is running
1 location listed.
- Royal National Hospital for Rheumatic Diseases - Bath, Somerset, United Kingdom